Published in N Engl J Med on November 13, 2011
Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access | NCT02475837
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice. J Thromb Haemost (2014) 1.54
Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood (2015) 1.39
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc (2015) 1.24
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin. J Biol Chem (2013) 1.04
PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest (2012) 1.00
Independent data monitoring committees: preparing a path for the future. Am Heart J (2014) 0.97
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation (2012) 0.94
Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost (2015) 0.94
Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett (2012) 0.94
Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. Crit Care (2012) 0.94
Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol (2013) 0.93
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. J Am Heart Assoc (2015) 0.92
Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol (2014) 0.91
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) (2013) 0.90
Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. Cardiovasc Diagn Ther (2016) 0.89
Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Vasc Health Risk Manag (2016) 0.88
Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets. PLoS One (2013) 0.86
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res (2012) 0.86
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes (2015) 0.85
Mechanisms of Platelet Activation and Integrin αIIβ3. Korean Circ J (2012) 0.85
Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program (2014) 0.85
Protease-activated receptor 4: from structure to function and back again. Br J Pharmacol (2016) 0.85
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis. J Biol Chem (2013) 0.84
Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J (2015) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Harnessing the platelet signaling network to produce an optimal hemostatic response. Hematol Oncol Clin North Am (2013) 0.82
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα. Redox Biol (2015) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Br J Pharmacol (2012) 0.80
Rare platelet GPCR variants: what can we learn? Br J Pharmacol (2014) 0.80
Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene (2015) 0.80
Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost (2014) 0.79
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag (2014) 0.79
Differential signaling by protease-activated receptors: implications for therapeutic targeting. Int J Mol Sci (2014) 0.78
Plasmin Activation of Glial Cells through Protease-Activated Receptor 1. Patholog Res Int (2013) 0.78
Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78
Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Ther Clin Risk Manag (2014) 0.77
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol (2012) 0.77
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc (2014) 0.77
Thrombin receptor antagonism in antiplatelet therapy. Cardiol Ther (2013) 0.77
Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77
Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets. PLoS One (2016) 0.77
Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy? Arterioscler Thromb Vasc Biol (2014) 0.77
Role of Opioid Receptors Signaling in Remote Electrostimulation - Induced Protection against Ischemia/Reperfusion Injury in Rat Hearts. PLoS One (2015) 0.77
Preventing platelet thrombosis with a PAR1 pepducin. Circulation (2012) 0.77
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol (2016) 0.76
Protease-activated receptors in hemostasis. Blood (2016) 0.76
Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. J Thromb Thrombolysis (2013) 0.76
Oral antiplatelet therapy in acute coronary syndromes: recent developments. Cardiol Ther (2013) 0.75
Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLoS One (2015) 0.75
Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar. ACS Med Chem Lett (2014) 0.75
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J (2015) 0.75
Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol (2017) 0.75
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol (2011) 0.75
Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Des Devel Ther (2015) 0.75
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. J Am Heart Assoc (2015) 0.75
Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar. ACS Med Chem Lett (2013) 0.75
Pharmacology: a new bleeding issue. Br Dent J (2014) 0.75
PAR-1 inhibitor antiplatelet agents: performance below par? Indian Heart J (2012) 0.75
When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome? Arq Bras Cardiol (2016) 0.75
Ticagrelor and heart surgery controversy: we may have better antiplatelet options. J Thorac Dis (2016) 0.75
Representation of older adults in the late-breaking clinical trials American Heart Association 2011 Scientific Sessions. J Am Coll Cardiol (2012) 0.75
Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc (2015) 0.75
Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75
Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Curr Cardiol Rev (2012) 0.75
Acute coronary syndromes: Thrombin-receptor antagonist increases bleeding in patients with ACS. Nat Rev Cardiol (2011) 0.75
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial. Cardiovasc Ther (2014) 0.75
Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea. Ther Clin Risk Manag (2016) 0.75
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation (2016) 0.75
Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Drugs R D (2017) 0.75
Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol (2017) 0.75
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Ther Clin Risk Manag (2015) 0.75
Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci (2016) 0.75
Antiplatelet agents in clinical practice and their haemorrhagic risk. Blood Transfus (2013) 0.75
Optimal choice of coronary revascularization and stent type in diabetic patients with coronary artery disease. Cardiol Ther (2013) 0.75
Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism. Thromb Res (2012) 0.75
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol (2016) 0.75
Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Mol Pharmacol (2016) 0.75
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
Biomarkers in acute coronary artery disease. Wien Med Wochenschr (2012) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Universal definition of myocardial infarction. Circulation (2007) 11.69
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Universal definition of myocardial infarction. Eur Heart J (2007) 9.04
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Universal definition of myocardial infarction. J Am Coll Cardiol (2007) 8.68
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol (2008) 7.56
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42